Brazilian Strategy to Create a Local Biotech and CMO Industry

Flavio Valente of EMD Serono joined us for World Biosimilar Congress USA 2016 to discuss ‘ Brazilian strategy to create a local biotech and CMO industry ‘. Download this presentation to understand more about: EMD Serono and its Biosimilars unit Biosimilars opportunity in Brazil Productive Development Partnership (PDPs) Merck – Binovis Partnership Brazilian Biotechnology and CMO Industry and more ! …

What happens to Biosimilars being developed under 505b (2)?

Nitesh Dave of Biocon joined us for World Biosimilar Congress USA 2016 to discuss what happens to biosimilars being developed under 505b (2). Download this presentation to understand more about: Key features of 505b (2) Key features of 351k (1, 2) Products approved under 505b (2) Path ahead for products under development and more! Get your copy here! If you’re interested …

Francisco Kuribreña of Landsteiner Scientific's 2015 Presentation

Landsteiner Scientific on Mexican biosimilars

We were excited to have Francisco Kuribreña, Director of New Development at Landsteiner Scientific, share his expertise on institutional experiences in preclinical evaluation of biosimilars in Mexico at last year’s World Biosimilar Congress USA. Download his presentation now > You can now download Francisco’s presentation to find out more about: The emerging Mexican economy Mexico and the pharma business The …

Doug Monroe of Kaiser Permanente's 2015 Presentation

Kaiser Permanente: the impact of biosimilars on private reimbursement

We were excited to have Doug Monroe, Project Manager of Biotechnology, Emerging Technology, and Specialty Pharmacy at Kaiser Permanente, share his expertise on the impact of biosimilars on private reimbursement strategies at the World Biosimilar Congress USA. Download his presentation now > You can now download Doug’s presentation to find out more about: The Kaiser Permanente integrated health care delivery system …

Ira Jacobs of Pfizer's 2015 Presentation

Pfizer shares their expertise on biosimilars on the horizon

Doctor Ira Jacobs is a fellowship trained surgical oncologist who is currently Pfizer’s oncology biosimilars global medical lead. Prior to Pfizer, Doctor Jacobs worked as a medical director in oncology global development at Amgen. He led clinical development programs in breast, lung, prostate, and bone cancers. Prior to transitioning into industry, Dr. Jacobs was a staff surgical oncologist. We were …

Ensuring Regulatory Compliance Quality And Safety In Biosimilars Production

Ensuring Regulatory Compliance Quality And Safety In Biosimilars Production

At BioPharma India Convention 2014, Samuel Raj Solomon, PhD., RAC (US & EU) Sr. Manager & Head -Biosimilars Regulatory Sciences, Biocon Ltd. India presented on the topic : Ensuring Regulatory Compliance Quality And Safety In Biosimilars Production. Download the presentation to learn: Central Dogma Of Biosimilars Manufacturing Regulatory Compliance For Biosimilars Manufacturing Systematic Risk And Science Based Approach – CQA Hallmarks Of Pivotal CMC …

Thomson reuters report

Thomson Reuters press-release: World Generic Medicines Congress Europe

The World Generic Medicines Congress Europe organized by Health Network Communications brought together industry stakeholders, decision makers, and experts for two days of presentations and discussions focused on market challenges and portfolio strategy. The industry has seen a collapse of traditional commodity generic models, while a new model is emerging from innovation and consolidation, supported by strategic geographic expansion. The …

Biooutsource

Biosimilars have caused a revolution in the development of biologic drugs

Remsima Case Study: The importance of ADCC in assessing clinically relevant differences Authors: Dr. Daniel Galbraith, Chief Scientific Officer and Andy Upsall, Director of Technical Services – BioOutsource Ltd. The Regulatory Authorities Verdict “Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental …

Bloomberg Biosimilar Survey

Take part in the Biosimilars Survey – Bloomberg Intelligence

Bloomberg Intelligence have launched the Biosimilars Survey. This is your opportunity to have your voice heard. Take part in the survey here > All responders will receive a white paper and analysis of the results. That’s not all! All responders will also receive a 15% discount code off the delegate ticket price for World Biosimilar Congress USA 2015, where Bloomberg will be …